Mitchell Cairo
Distinguished in Osteosarcoma

Dr. Mitchell Cairo

Pediatrics
Cardiology Consultants
19 Bradhurst Ave, 
Hawthorne, NY 
46 Years of Experience
Distinguished in Osteosarcoma
Cardiology Consultants
19 Bradhurst Ave, 
Hawthorne, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mitchell Cairo is a Pediatrics provider in Hawthorne, New York. Dr. Cairo has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 225 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Osteosarcoma.

Specialties
Pediatrics
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Cardiology Consultants
19 Bradhurst Ave, Hawthorne, NY 10532
Other Locations
Arlene G. Adler PhD
19 Bradhurst Ave Ste 1400, Hawthorne, NY 10532

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)
Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drug: CD34-Positive T Cell-Depleted Allogeneic Stem Cell Transplant
Study Phase: Phase 2
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
Enrollment Status: Completed
Publish Date: December 08, 2023
Intervention Type: Drug
Study Drug: Defibrotide
Study Phase: Phase 2
A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome
A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: October 26, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 2
Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)
Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)
Enrollment Status: Completed
Publish Date: October 26, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 2
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients Following Ganciclovir Prophylaxis Until Day +100
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients Following Ganciclovir Prophylaxis Until Day +100
Enrollment Status: Completed
Publish Date: October 26, 2023
Intervention Type: Drug
A Safety and Feasibility Study of Autologous Cord Blood (CB) and Human Placental Derived Stem Cells (HPDSC) in Neonates With Severe Hypoxic-Ischemic Encephalopathy (HIE)
A Safety and Feasibility Study of Autologous Cord Blood (CB) and Human Placental Derived Stem Cells (HPDSC) in Neonates With Severe Hypoxic-Ischemic Encephalopathy (HIE)
Enrollment Status: Withdrawn
Publish Date: February 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase I Clinical Trial of Pooled Red Blood Cells for Transfusion
Phase I Clinical Trial of Pooled Red Blood Cells for Transfusion
Enrollment Status: Withdrawn
Publish Date: December 26, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 7 Less Clinical Trials

225 Total Publications

Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trial.
Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trial.
Journal: Haematologica
Published: December 16, 2025
Similar Doctors
Distinguished in Osteosarcoma
Dr. Robert Maki
Hematology Oncology | Oncology | Pediatrics
Distinguished in Osteosarcoma
Dr. Robert Maki
Hematology Oncology | Oncology | Pediatrics

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (23.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Maki is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Maki is rated as an Elite provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Gastrointestinal Stromal Tumor, and Undifferentiated Pleomorphic Sarcoma.

Julie I. Krystal
Advanced in Osteosarcoma
Dr. Julie I. Krystal
Pediatric Hematology Oncology | Pediatrics | Oncology
Advanced in Osteosarcoma
Dr. Julie I. Krystal
Pediatric Hematology Oncology | Pediatrics | Oncology

Northwell Health Pediatric Hematology/Oncology & Stem Cell Transplant

269-01 76th Avenue, Suite 255, 
New Hyde Park, NY 
 (23.6 miles away)
718-470-3460
Languages Spoken:
English
See accepted insurances

Julie Krystal is a Pediatrics specialist and an Oncologist in New Hyde Park, New York. Dr. Krystal is rated as an Advanced provider by MediFind in the treatment of Osteosarcoma. Her top areas of expertise are Neuroblastoma, Medulloblastoma, Acute Lymphoblastic Leukemia (ALL), Rhabdomyosarcoma, and Bone Marrow Aspiration.

Experienced in Osteosarcoma
Dr. Mehmet Ozkaynak
Pediatrics
Experienced in Osteosarcoma
Dr. Mehmet Ozkaynak
Pediatrics

WMcHealth Physicians Advanced Ob/Gyn Associates-Maternal-Fetal Medicine Middletown

100 Crystal Run Rd Ste 108, 
Middletown, NY 
 (39.5 miles away)
914-493-7997
Languages Spoken:
English
See accepted insurances

Mehmet Ozkaynak is a Pediatrics provider in Middletown, New York. Dr. Ozkaynak is rated as an Advanced provider by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Adenoidectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cairo's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 11 Distinguished Conditions
View All 8 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile